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cases. This pattern is typical for coagulopathy-induced as 
well as other nonhypertensive causes of intracerebral hem- 
orrhage (39). Intracerebral hemorrhage has frequently been 
reported to occur during (30,31,35) and usually 524 h 
(13+19,20,29,35,36) after infusion of the fibrinolytic 
agent. Although isolated case reports of intracerebral hem- 
orrhage have been associated with severe hypofibrinogen- 
emia (31,34), several studies (30,38,40) have shown a poor 
correlation between the existence of a lytic state and in- 
tracerebral bleeding. The presence ofa markedly prolonged 
activated partial thromboplastin me and a higher dose 
per body weight (for example, women with smaller body 
size) may have contributed to intracerebral bleeding in 
some cases (24,30,31,34,37,39). Other disease processes. 
such as cerebral congophilic amyloid angiopathy or unde- 
fined preexisting vascular lesions in the brain, may be 
unmasked by thrombolytic therapy protocols and lead to 
brain hemorrhages (2434-37). Detailed neurodiagnostic 
evaluation and pathologic data on this critical point are 
virtually nonexistent; in only one case has histologic 
examination f brain tissue from the wall of an intracerebral 
hematoma been performed, the result of which was normal 
(34). 
Prognosis. In addition, the prognosis of patients with 
myocardial infarction who have cerebrovascular events 
after thrombolytic therapy may be improving (14-16,19,20, 
29-31,34,37). The overall mortality rate ranges between 
28% (20) and 43% (14,15). Whereas the mortality rate in 
patients with intracerebral hemorrhage may be as high 
as 70% (13,17,20,30,31,34-37), more recent studies uggest 
that the acute mortality rate has been reduced to 44% (37) 
and 52% (35,36). This reduction may reflect more careful 
patient selection, better control of the dosage of the fibrin- 
olytic agent and concomitant therapies, and in some in- 
stances, aggressive medical or surgical management, or 
both. 
The present study. In this issue of the Journal, O’Connor 
et al. (41) report on the occurrence of ischemic stroke and 
intracranial hemorrhage complicating the Thrombolysis and 
Angioplasty in Myocardial Infarction (TAMI) I, II and III 
trials. Thirteen (1.8%) of 708 patients treated with various 
doses of &PA or urokinase, orboth, had a stroke: 4strokes 
(0.6%) were hemorrhagic and 9 (1.3%) were ischemic, of 
which 8 were cardioembolic. Only the occurrence of a large 
anterior myocardial infarction (with ejection fraction ~45%) 
was a predictor of ischcmic stroke (p = O.OOlS). This finding 
is not surprising. No prespecified risk factor was helpful in 
predicting the occurrence of hemorrhagic stroke, Depressed 
level Of consciousness and large lesions on the computed 
tomographic (CT) scan with midline shift were more com- 
mon in the patients with hemorrhagic stroke. The mortality 
rate for ischemic and hemorrhagic strokes was 11% and 
25%. respectively. 
This study is important inthat it pools the stroke xperi- 
ence in three large thrombolyt~c therapy trials with system- 
atic evaluation and follow-up of stroke patients. AltRough 
the incidence of cerebrovascu!ar events is somew 
than in recently published series (13- PS,l9,20), 
reflec? the small number of patients enrolled in th 
well as the careful, prospective r cognition and evaluation of
cases by a dedicated neurologist. By contrast, he mortality 
rates are quite low, which may be because of excellent 
patient care or exclusion of patients at high risk of 
death, or a combination f these. It is clear that dev 
of a change in Bevel of consciousness, headache, focal 
neurologic symptoms orseizures during or soon after thro 
boiytic therapy should be viewed witb a high index of 
suspicion and that CT scanning must be performed immedi- 
ately to distinguish among intracranial hemorrhage, c rebral 
infarction and the effects of severe cardiac dysfunction or 
concomitant myocardial infarction therapy, or both. 
The present study ;41) has two weaknesses. First, as the 
authors tate, the small number of obscrvatioiis prcchide 
statistically meaningful assessment of predictors for intra- 
cerebral hemorrhage, including aspirin use and degree of 
hypofibrinogenemia, which would influence the bleeding 
time and activated partial tbrombo~lasti~ me values. 
Moreover, it is not clear that the bleeding times, fibrinogen 
levels and activated partial thromboplastin times for 
the stroke patients are different from those patients with- 
out a cerebrovascuiar complication. The contribution of 
heparin therapy to the occurrence of intracerebral hemor- 
rhage is incompletely understood (24). Second, the precise 
site, the occurrence of blood pressure fluctuations and the 
temporal profile of illness in the paGents with hemorrhagic 
c’troke were not clear. Nonetheless, the authors have made a 
valuable contribution by describing a method to obtain a 
better understanding of the risk of specific erebrovascuiar 
complications of thrombolytic herapy for myocardial infarc- 
tion. 
Implications. It is hoped that future studies will apply 
similar methodologies to gain insights islto risk factors for 
ischemic and hemorrhagic stroke in this setting. Although it
may not be possible to totally eliminate the occurrence of
stroke after thrombolytic therapy for myocardiai infarction, 
neurodiagnostic evaluation and pathologic description of 
adequate numbers of cases of cerebral infarction and intra- 
cerebral hemorrhage and associated factors may permit 
delineation of their mechanisms and suggest appropriate 
preventive measures. It IS clearly important to be able to 
distinguish parenchymatous intracerebral hemorrhage 
from cerebral infarction with hemorrhagic transformation as 
their appearance onthe CT scan may be identical (29,32). 
We urge investigators in ongoing large thrombolytic therapy 
trials to work closely with neurologists and neuropatholo- 
gists to facilitate the realization ofthis objective. Only ti:pp 
can we begin to make a significant impact on the burden of 
neurologic mortality and morbidity in patients uccessfully 
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